Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J LORD

Showing results (481-490 of 511) with videos related to

Pageof 52
Sort By:
Scientific Reports|July 15, 2018
Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAnessHarriett Holme, Aditi Gulati, Rachel Brough, et al.
Cancer Research|June 25, 2017
Functionally Null <i>RAD51D</i> Missense Mutation Associates Strongly with Ovarian CarcinomaBarbara Rivera, Massimo Di Iorio, Jessica Frankum, et al.
Scientific Reports|August 23, 2018
Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAnessHarriett Holme, Aditi Gulati, Rachel Brough, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalityJean Ching-Yi Tien, Yu Chang, Yuping Zhang, et al.
Cancer Research|October 16, 2024
Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell TumorsAsuka Kawai-Kawachi, Madison M Lenormand, Clémence Astier, et al.
Cancer Cell|November 22, 2024
Elucidating acquired PARP inhibitor resistance in advanced prostate cancerGeorge Seed, Nick Beije, Wei Yuan, et al.
Nature Communications|March 12, 2026
Tumour specific HORMAD1 expression perturbs mitotic arrest and drives sensitivity to mitotic kinase inhibitorsCallum Walker, Gabriel Kollarovic, Daniel Weekes, et al.
Cell Reports. Medicine|October 5, 2024
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Jean Ching-Yi Tien, Jie Luo, Yu Chang, et al.
NPJ Precision Oncology|July 11, 2026
Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling programHeura Domènech, Sara Simonetti, Paula Romero-Lozano, et al.
American Journal of Human Genetics|March 28, 2017
De Novo Truncating Mutations in the Last and Penultimate Exons of PPM1D Cause an Intellectual Disability SyndromeSandra Jansen, Sinje Geuer, Rolph Pfundt, et al.
Pageof 52

Showing results (481-490 of 511) with videos related to

Sort By:
Pageof 52
Scientific Reports|July 15, 2018
Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAnessHarriett Holme, Aditi Gulati, Rachel Brough, et al.
Cancer Research|June 25, 2017
Functionally Null <i>RAD51D</i> Missense Mutation Associates Strongly with Ovarian CarcinomaBarbara Rivera, Massimo Di Iorio, Jessica Frankum, et al.
Scientific Reports|August 23, 2018
Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAnessHarriett Holme, Aditi Gulati, Rachel Brough, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalityJean Ching-Yi Tien, Yu Chang, Yuping Zhang, et al.
Cancer Research|October 16, 2024
Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell TumorsAsuka Kawai-Kawachi, Madison M Lenormand, Clémence Astier, et al.
Cancer Cell|November 22, 2024
Elucidating acquired PARP inhibitor resistance in advanced prostate cancerGeorge Seed, Nick Beije, Wei Yuan, et al.
Nature Communications|March 12, 2026
Tumour specific HORMAD1 expression perturbs mitotic arrest and drives sensitivity to mitotic kinase inhibitorsCallum Walker, Gabriel Kollarovic, Daniel Weekes, et al.
Cell Reports. Medicine|October 5, 2024
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Jean Ching-Yi Tien, Jie Luo, Yu Chang, et al.
NPJ Precision Oncology|July 11, 2026
Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling programHeura Domènech, Sara Simonetti, Paula Romero-Lozano, et al.
American Journal of Human Genetics|March 28, 2017
De Novo Truncating Mutations in the Last and Penultimate Exons of PPM1D Cause an Intellectual Disability SyndromeSandra Jansen, Sinje Geuer, Rolph Pfundt, et al.
Pageof 52